Dr. Raja Prince-Eladnani is a translational scientist and biotech entrepreneur with more than 15 years of experience in hemostasis, thrombosis, bleeding disorders, inflammation, and therapeutic innovation.

She holds a Bachelor’s degree in Biology from Mohammed V University in Rabat, Morocco, and a Master’s degree in Toxicology from the University of Lille, France. She obtained her PhD through the International Program in Cancer and Immunology at the University of Lausanne, where she developed expertise at the interface of inflammation, coagulation, and translational biomedical research.

After completing her Master’s training, Dr. Prince-Eladnani worked as a clinical research associate in oncology and blood diseases. Following her doctoral studies, she joined the University of Bern and Inselspital Bern, where she completed postdoctoral training in the Department of Biomedical Research and the Department of Hematology and Central Hematology Laboratory. She subsequently became Senior Scientist, leading and supervising translational research projects in rare bleeding disorders, sepsis, novel anticoagulant strategies, and myeloproliferative neoplasms.

Her research focuses on the mechanisms regulating hemostasis and thrombosis, with a particular emphasis on Protein S biology and its therapeutic potential in hemophilia and rare bleeding disorders. She played a central role in establishing Protein S as a druggable target to rebalance coagulation and protect against bleeding-induced joint and bone damage.

Dr. Prince-Eladnani also holds a Master of Advanced Studies in Translational Medicine and Entrepreneurship from the Swiss Institute for Translational and Entrepreneurial Medicine in Bern. In 2025, she co-founded BLEEDnFIRE Therapeutics, a University of Bern spin-off developing first-in-class RNA-based therapies targeting Protein S to prevent bleeding and joint/bone damage. She has secured multiple competitive grants and awards, including support from Innosuisse, Venture Kick, Gebert Rüf Stiftung, Unitectra, the University of Bern, and the Swiss Hemophilia Network.

Daan Kok is an international life sciences executive with over 20 years of experience in commercial operations, business development, and strategic growth across biotech, MedTech, and consumer goods. In addition to his role as CBO of Landmark BioVentures AG, he also serves as interim COO to LBV nexus companies Duhn Therapeutics and BleednFire, with a focus on portfolio strategy, partnerships, and acquirer-backwards positioning.

Daan currently serves as Head of Business Development & Strategy at Hemanext Inc., where he leads fundraising and commercial strategy, having previously served as EVP and General Manager EMEA. He successfully closed an $18.9M Series B financing and is currently leading the Series C fundraising process. Daan also supports operations and finance at Eldian Biomed, a spin-out of the University of Bern.

Previously, Daan held roles of increasing responsibility at bluebird bio GmbH (2017–2021), where he served as General Manager & VP Expansion Markets EMEA and Head of the ALD Franchise Europe, leading regional expansion, establishing gene therapy treatment centers, and coordinating market access across Europe and the Middle East. Prior to bluebird bio, Daan spent a decade at Celgene (2007–2017) in senior roles spanning Finance, Market Access, and Business Unit Leadership across Neuchâtel, Munich, Utrecht, Brussels, and Stockholm, with full P&L responsibility exceeding USD 200 million and product launches across 10+ markets. He began his career in investment banking at Lazard in London, followed by financial roles at Procter & Gamble, where he managed a USD 1+ billion market cluster across the UK, Nordics, and BeNeLux.

Daan earned a Master in International Business Studies from Maastricht University, The Netherlands (2004), studied at HEC Lausanne, Switzerland and is a Fellow of the Chartered Institute of Management Accountants (FCMA, CGMA). He has completed executive education in Private Equity at CFA (UK), AI & Business Strategy at MIT, and Negotiation Strategies at INSEAD.

Dr. Remo Gamboni is a leading expert in RNA therapeutics and pharmaceutical development, with more than 35 years of experience across the full spectrum of drug development, from early discovery through CMC and into clinical development. He has held senior positions in both biotech and major pharmaceutical organizations, including Novartis, Roche and CIBA, where he contributed to the development of advanced therapeutic platforms.

He is widely recognized for his work in oligonucleotide-based therapeutics, playing a key role in translating novel RNA technologies into scalable and clinically viable medicines.

As Head of CMC and a founding member of BLEEDnFIRE Therapeutics, he is responsible for advancing the company’s siRNA-based approach targeting Protein S, bridging cutting-edge science with industrial execution.

Prof. Anne Angelillo-Scherrer is a leading clinician-scientist in hematology with more than 25 years of experience in coagulation, thrombosis, and translational medicine.

She studied medicine at the University of Geneva and completed her doctoral thesis at the University of Lausanne in 1993. She trained in oncology, internal medicine, and hematology at the University Hospitals of Geneva, obtaining board certification in both internal medicine and hematology in 1999. Following a postdoctoral fellowship at the University of Leuven (Belgium), she established her own research group at the University Hospitals of Geneva, focusing on angiogenesis and hemostasis.

From 2005 to 2011, she served as a Swiss National Science Foundation Professor and Senior Physician at the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, where she led clinical and laboratory activities in hematology. She was subsequently appointed Associate Professor of Hematology at the University of Lausanne.

Her research focuses on the mechanisms of blood coagulation and thrombosis, particularly in the context of inflammation, as well as the pathophysiology of anemia. Her work has been instrumental in advancing the understanding of Protein S as a therapeutic target.

Since 2013, Prof. Angelillo-Scherrer has been Director and Chief Physician of the University Clinic for Hematology and the Central Hematology Laboratory at Inselspital Bern, and Full Professor (Ordinaria) of Hematology at the University of Bern.

Zaki Sellam is an experienced C-level biotech executive, with over two decades of experience and leadership in cancer/immunology drug discovery, translational medicine, clinical development, biotech startups, and fostering strategic alliances between prominent pharmaceutical companies and academic institutions. Mr. Sellam has raised approximately $100 million in equity financing in this sector. In addition to his role as CEO of Landmark BioVentures AG, he also serves as Executive Chairman to each of LBV nexus companies.

Previously, Mr. Sellam was Founder and CEO of Avicenna Oncology GmbH, an Antibody Drug Conjugate start up located in Basel (2014-2019). Mr. Sellam also advises start-up companies, (including Iome Bio, Harvard spin off), Tech Transfer Accelerators and pharma companies (including OM Pharma) through his strategic consulting firm ESN Life Sciences GmbH (2011-present).

Mr. Sellam earned an MS in Biotechnology Engineering from the National School of Biotechnology in Bordeaux, France (2002) and an MBA from the Institute of Business Administration in Poitiers, France (2007).